Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 4/20 | 0.51 |
| ▸ | JAK2 | O60674 | 3/20 | 0.48 |
| ▸ | BRD4 | O60885 | 3/20 | 0.48 |
| ▸ | JAK1 | P23458 | 2/20 | 0.45 |
| ▸ | PAK4 | O96013 | 3/20 | 0.43 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
| ▸ | CHUK | O15111 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4920915 | 0.82 | JAK2 (0.50) | PTK2JAK2BRD4JAK1PAK4 | |
| SCHEMBL4914873 | 0.80 | PAK4 (0.63) | JAK2BRD4PAK4 | |
| SCHEMBL4649832 | 0.80 | PTK2 (0.50) | PTK2JAK2BRD4JAK1EPHB4 | |
| SCHEMBL4909551 | 0.79 | JAK2 (0.51) | PTK2JAK2BRD4JAK1PAK4 | |
| SCHEMBL4917628 | 0.79 | JAK2 (0.59) | PTK2JAK2BRD4PAK4 | |
| SCHEMBL4909586 | 0.79 | JAK2 (0.59) | PTK2JAK2BRD4PAK4 | |
| SCHEMBL4914224 | 0.79 | JAK2 (0.51) | PTK2JAK2BRD4JAK1PAK4 | |
| SCHEMBL4920465 | 0.78 | TTK (0.51) | PTK2JAK2BRD4PDPK1 | |
| SCHEMBL4918495 | 0.77 | JAK2 (0.46) | PTK2JAK2BRD4JAK1PAK4 | |
| SCHEMBL4915798 | 0.77 | JAK1 (0.41) | PTK2JAK2BRD4JAK1EPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
| EP-1966210-A2 | SULPHONAMIDOANILINE DERIVATIVES BEING JANUS KINASES INHIBITORS | Novartis AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071393-A2 | SULPHONAMIDOANILINE DERIVATIVES BEING JANUS KINASES INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| WO-2005037839-A1 | NORCANTHARIDIN DERIVATIVE COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF, COMPOSITIONS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | ENTOMED (FR) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | GRK4, JAK2, ALK | PTK2 1036/4885JAK2 2/4885BRD4 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.